Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects

Ludwig-Maximilians - University of Munich35 enrolled

Overview

This study is an investigation of the dopaminergic neurotransmission in patients with schizophrenia, patients at risk for the development of schizophrenia, and healthy controls using an iodobenzamide-single photon emission computed tomography (IBZM-SPECT) imaging technique under amphetamine challenge.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Schizophrenia

Interventions

IBZM-SPECT (bolus and constant infusion paradigm)PROCEDURE

single IBZM-SPECT assessment at study inclusion

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of schizophrenia (currently unmedicated) * Subjects at risk for the development of schizophrenia (prodromal symptoms) * Healthy subjects * Written informed consent Exclusion Criteria: * Neurological or severe somatic disorders * Women during pregnancy or lactation * Occupational exposition to radiation \> 15mSv * Medication known to interfere with IBZM * Contraindications for the use of amphetamine challenge

Locations (2)

Dept. of Psychiatry

Munich, Germany

Dept. of Nuclear Medicine

Munich, Germany

Outcomes

Primary Outcomes

dopamine receptor availability

Time frame: cross-sectional

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.